UCLA Health researchers have identified a molecule, DDL-920, that restores cognitive functions and memory in Alzheimer's disease model mice by enhancing brain electrical rhythms. Unlike current FDA-approved Alzheimer’s drugs, DDL-920 revitalizes memory rather than just slowing decline. The study, led by Drs. Istvan Mody and Varghese John, represents a novel approach to Alzheimer's treatment, with potential applications for other conditions such as schizophrenia and depression.